News Lilly names Pennsylvania site for its latest US facility Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.
News AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.
News AbbVie turbocharges its US investment promise to $100bn AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing HSA growth and the opportunities emerging for investors and ... Paying attention to the intersection of public policy and business opportunity can be a winning strategy for start-ups and disrupters.
Market Access Why the NHS remains the world's most challenging – and rewar... For pharmaceutical, biotech, and medtech companies eyeing global expansion, the NHS presents a paradox.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.